Developer docs
API playgroundTry for free, no card

Search company profiles

Milestone

Full company profile

uuid00034t9

Namestring
Milestone
Legal namestring
妙顺(上海)生物科技有限公司
Websiteurl
miles-bio.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Milestone (妙顺生物), founded in 2014 and headquartered in Shanghai's Zhangjiang district, is a privately held Chinese life-sciences tools and services company specializing in primary cell isolation, separation, and cryopreservation for the biopharmaceutical and cell-and-gene-therapy (CGT) industries. The company's core technology is its proprietary TPCS (The Primary Cell Solution) platform, which uses density gradient centrifugation and immunomagnetic separation to deliver standardized primary cells including PBMC, immune cell subsets (T cells, B cells, NK cells, monocytes), liver cells, and disease patient-derived cells, supported by a near 2,000 m2 R&D and production base in the Zhoushan Free Trade Zone. It has expanded the technology stack with the MileCell MagSep nanomagnetic bead cell sorting platform (2025), Kryogene DMSO-free cryopreservation solution, and Kryoplus serum-free media series, alongside animal primary cells, subcellular fractions (microsomes, S9, lysosomes), SLC transporter cell lines, and biological matrices.

Milestone operates a hybrid revenue model combining one-time product sales (primary cells, subcellular fractions, reagents, magnetic separation beads and kits), professional services (custom cell isolation, hPB Leukopak collection, cryopreservation, cold chain logistics), and CRO services (ADCC/ADCP assays, MLR testing, cytokine detection, drug efficacy evaluation in primary cell models). Pricing is custom-quoted per specifications, donor profile, and volume. The go-to-market is B2B sales-led, targeting biopharmaceutical companies, CGT developers, and academic research institutions via key account coverage, conference exhibitions (AACR, BIO, CGCS, QbD, I-CAR), and an integrated marketing presence on WeChat, Douyin, and other Chinese channels. The company claims over 2,000 partner organizations and explicitly positions itself as a domestic import-substitution player addressing China's 'bottleneck' in upstream biopharma research materials, with US ambitions managed through a San Diego office.

Milestone is backed by state-backed Zhongke Haichuang and Yida Capital following its 2023 Series A (over RMB 100M), and by Xingzheng Capital following its 2025 Series A+ (near RMB 100M), with Hillhouse's GL Ventures, Titan Technology, and Tongyu Fund as co-investors. The company is led by founder and CEO Zhang Jinbao, with a chief scientific officer trained at Tsinghua and the University of Basel. It holds ISO 9001/14001/45001 certifications, has been recognized as a National High-Tech Enterprise and Shanghai 'Specialized, Refined, Differential and Innovative' SME, and has led the drafting of a group standard for cell therapy Leukopak raw materials while participating in a national PBMC preservation standard.

Short descriptiontext

Milestone (妙顺生物) is a Shanghai-based Chinese life-sciences tools company founded in 2014 that provides primary cells, cryopreservation reagents, magnetic separation platforms, and CRO services to biopharmaceutical companies, cell-and-gene-therapy developers, and academic research institutions, positioning itself as a domestic import substitute for upstream biopharma research materials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersZhangjiang, China
HQ citystring
Zhangjiang
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
primary cell isolation, cell therapy services, cryopreservation solutions, subcellular fractions, drug discovery services
Industry4 codes
PRIMARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAK
Cell Therapy Quality, Analytics & Release Testing (potency, sterility, comparability)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Medical Laboratories8071
Product category
Biotechnology Research Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Primary Cell Products
TypeOne Time License
Description

One-time sale of isolated primary cells including PBMC, immune cell subsets (T cells, B cells, NK cells, monocytes), liver cells, and subcellular fractions (microsomes, S9 fraction). Revenue from direct product sales to biopharma companies and research institutions.

miles-bio.com
2Cell Isolation and Separation Services
TypeProfessional Services
Description

Custom primary cell isolation services including hPB Leukopak collection, PBMC separation, immune cell subset isolation. Services include quality control, cryopreservation, and cold chain logistics.

miles-bio.com
3Biological Reagents and Consumables
TypeHardware Sales
Description

Sale of cell culture media, cryopreservation solutions, magnetic separation beads, and related reagents. Consumable products with recurring purchase patterns.

miles-bio.com
4Drug Development Platform Services
TypeProfessional Services
Description

CRO services including ADCC/ADCP assay, MLR testing, cytokine detection, and drug efficacy evaluation using primary cell models.

miles-bio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1Custom pricing based on cell type, species, donor characteristics, and service specifications
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing varies based on product specifications (e.g., 0.5 million cells per vial), donor screening requirements (healthy vs. disease patient), and service scope (standard vs. custom isolation protocols).

miles-bio.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1TPCS® (The Primary Cell Solution)
Description

Self-developed brand platform providing primary cell isolation services, cell culture reagents, and comprehensive cell technology services for drug discovery and development.

miles-bio.com
+3 more records
Core offering1 text field

Milestone (妙顺生物 / MileCell) provides primary cell isolation, separation, and cryopreservation products and services for biopharmaceutical companies, cell and gene therapy developers, and academic researchers. Its core offering is the proprietary TPCS platform delivering human primary cells (PBMC, immune cell subsets, liver cells, stem cells), animal primary cells across multiple species, subcellular fractions (microsomes, S9, lysosomes), biological matrices, SLC transporters, and cryopreservation reagents. It also offers tumor immunology CRO services including ADCC/ADCP assays, MLR testing, and drug efficacy evaluation using primary cell models.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Cell viability ≥90% for frozen PBMC and immune cell products
+2 more records
Product and service11 records
1Human Primary Cells — Healthy Donor & Disease Patient-Derived
CategoryPrimary cells
Description

Catalog and custom-isolated human primary cells sourced from healthy donors and disease patients, for use by biopharmaceutical R&D, cell therapy developers, and academic researchers in immunology, oncology, and regenerative medicine studies.

2Animal Primary Cells
CategoryPrimary cells
Description

Multi-species animal primary cells for preclinical drug discovery, including immune cells, hepatocytes, intestinal epithelial cells, kidney proximal tubular epithelial cells, skeletal muscle cells, and brain microvascular endothelial cells for in vivo and in vitro pharmacology studies.

3Subcellular Fractions (Microsomes, S9, Lysosomes)
CategorySubcellular fractions
Description

Subcellular fractions including liver microsomes, intestinal microsomes, liver S9, intestinal S9, induced liver S9, and liver lysosomes for ADME/DMPK and drug metabolism studies.

4SLC Transporters (OAT1, OCT2, MOCK)
CategoryTransporter cell lines
Description

Overexpression cell lines for SLC drug transporters OAT1 and OCT2 plus MOCK control cells, used in drug-drug interaction and renal/hepatic transport studies.

5Biological Matrices (Bio-matrix)
CategoryBiological matrices
Description

Healthy human donor biological matrices including blood-derived bio-matrix, other biological fluids, and tissue matrices used as assay matrices and reference standards.

6Kryogene™ DMSO-Free Cryopreservation Solution
CategoryCryopreservation reagents
Description

Clinical-grade DMSO-free cryopreservation medium for immune cells, stem cells, and other primary cell types, eliminating the cytotoxic risks of DMSO while maintaining post-thaw viability and function.

7Kryoplus™ Serum-Free Cryopreservation Solutions
CategoryCryopreservation reagents
Description

Serum-free and xeno-free cryopreservation media for immune cells and mesenchymal stem cells, designed for cost-efficient and regulatory-friendly cell storage.

8MileCell MagSep™ Nanomagnetic Cell Separation Platform
CategoryCell separation platform
Description

Proprietary nanomagnetic bead-based platform for multi-dimensional immune cell sorting, including positive selection kits (CD3, CD4, CD8, CD14) and negative selection panels, used for cell therapy and immunology research.

9hPB Leukopak Collection Service
CategoryCell collection services
Description

Apheresis-based collection service for high-quality hPB Leukopak white blood cell samples, including healthy donor and mobilized donor collection plus irradiation and plateletpheresis/RBC/neutrophil collection options, for cell therapy raw material supply.

10Tumor Immunology & Drug Efficacy Evaluation CRO Services
CategoryCRO services
Description

CRO services for biopharmaceutical R&D including ADCC/ADCP assays, mixed lymphocyte reaction (MLR) testing, cytokine detection, and in vitro/in vivo drug efficacy evaluation using Milestone's primary cell models.

11Custom Primary Cell Isolation & Separation Services
CategoryCustom cell services
Description

Custom cell isolation and separation services for biopharma and cell therapy clients requiring tailored cell types, donor profiles, quality specifications, cryopreservation, and cold-chain logistics.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1MaoXing Bio (茂行生物)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-10-09
Description

Strategic partnership for universal CAR-T development. Miaoshun provides PBMC raw materials for MaoXing's MT027 glioblastoma CAR-T product, supporting IND filing.

miles-bio.com
2Xinxie Bio (欣协生物)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-09-14
Description

Strategic cooperation to provide comprehensive CGT solutions. Xinxie provides cell therapy equipment while Miaoshun provides cell raw materials.

miles-bio.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-08-30
Description

Strategic cooperation framework signed for preclinical drug discovery services integration. Combining Miaoshun's primary cells with Baijun's CRO platform to provide integrated drug discovery solutions.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-08-30
Description

Strategic partnership combining Miaoshun's cell products with Yinjia's protein technology platform to develop cell-related reagents for biopharma customers.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Canadian-headquartered leader in primary cell isolation products (PBMC, immune cell subsets, leukopak), cell culture media, and cell separation reagents — the most direct global competitor to Milestone's TPCS primary cell platform across both research and CGT-manufacturing use cases.

TypeDirect peer
Description

German provider of magnetic-bead cell separation (MACS), primary cells, leukopak, and cryopreservation media used across CGT manufacturing — directly comparable to Milestone's MileCell MagSep and TPCS offerings, and the global benchmark Milestone must displace in Chinese CGT labs.

TypeBroad incumbent
Description

Swiss CDMO and primary cell/media supplier with a large Cell & Gene Technologies business serving global CGT developers — competes with Milestone in cell therapy raw materials and process development services but as part of a much broader biomanufacturing portfolio.

TypeBroad incumbent
Description

US life-science tools company with primary cells, leukopak, cytokines, and cell therapy reagents (R&D Systems, Tocris, PeproTech) — overlapping with Milestone's reagent, cell, and media product lines as part of a much wider proteomics and diagnostics franchise.

TypeDirect peer
Description

Beijing-headquartered provider of recombinant proteins, cell biology reagents, magnetic beads, and CGT process consumables — directly competes with Milestone in China for cell isolation reagents, magnetic separation tools, and bioprocess consumables.

TypeDirect peer
Description

Chinese reagents and cell products supplier offering recombinant proteins, antibodies, and cell biology tools used in CGT and biopharma research — overlaps with Milestone's reagent and primary cell offerings for the same Chinese customer base.

TypeDirect peer
Description

German supplier of GMP-grade cell therapy raw materials including cryopreservation media, cytokines, and cell processing reagents — directly comparable to Milestone's Kryogene/Kryoplus and ancillary materials portfolio, particularly for clinical-grade cell therapy supply.

TypeDirect peer
Description

GenScript's CDMO arm offering plasmid, viral vector, and cell therapy process services from China and the US — competes with Milestone in cell therapy enabling services and adjacent upstream bioprocess support.

TypeBroad incumbent
Description

Large US CRO/CDMO with cell therapy services, primary cell products, and safety/analytics labs — overlaps Milestone's drug metabolism and cell-based CRO services, though Charles River operates across a far broader discovery-to-manufacturing portfolio.

TypeBroad incumbent
Description

China's largest CRO/CDMO offering preclinical drug discovery, biologics, and cell therapy services — competes with Milestone in biopharma CRO services and liver-cell-based DMPK assays, though at significantly greater scale and breadth.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Milestone

Biotechnology Research Servicesmiles-bio.com

Milestone (妙顺生物) is a Shanghai-based Chinese life-sciences tools company founded in 2014 that provides primary cells, cryopreservation reagents, magnetic separation platforms, and CRO services to biopharmaceutical companies, cell-and-gene-therapy developers, and academic research institutions, positioning itself as a domestic import substitute for upstream biopharma research materials.

What Milestone does

Milestone (妙顺生物), founded in 2014 and headquartered in Shanghai's Zhangjiang district, is a privately held Chinese life-sciences tools and services company specializing in primary cell isolation, separation, and cryopreservation for the biopharmaceutical and cell-and-gene-therapy (CGT) industries. The company's core technology is its proprietary TPCS (The Primary Cell Solution) platform, which uses density gradient centrifugation and immunomagnetic separation to deliver standardized primary cells including PBMC, immune cell subsets (T cells, B cells, NK cells, monocytes), liver cells, and disease patient-derived cells, supported by a near 2,000 m2 R&D and production base in the Zhoushan Free Trade Zone. It has expanded the technology stack with the MileCell MagSep nanomagnetic bead cell sorting platform (2025), Kryogene DMSO-free cryopreservation solution, and Kryoplus serum-free media series, alongside animal primary cells, subcellular fractions (microsomes, S9, lysosomes), SLC transporter cell lines, and biological matrices.

Milestone operates a hybrid revenue model combining one-time product sales (primary cells, subcellular fractions, reagents, magnetic separation beads and kits), professional services (custom cell isolation, hPB Leukopak collection, cryopreservation, cold chain logistics), and CRO services (ADCC/ADCP assays, MLR testing, cytokine detection, drug efficacy evaluation in primary cell models). Pricing is custom-quoted per specifications, donor profile, and volume. The go-to-market is B2B sales-led, targeting biopharmaceutical companies, CGT developers, and academic research institutions via key account coverage, conference exhibitions (AACR, BIO, CGCS, QbD, I-CAR), and an integrated marketing presence on WeChat, Douyin, and other Chinese channels. The company claims over 2,000 partner organizations and explicitly positions itself as a domestic import-substitution player addressing China's 'bottleneck' in upstream biopharma research materials, with US ambitions managed through a San Diego office.

Milestone is backed by state-backed Zhongke Haichuang and Yida Capital following its 2023 Series A (over RMB 100M), and by Xingzheng Capital following its 2025 Series A+ (near RMB 100M), with Hillhouse's GL Ventures, Titan Technology, and Tongyu Fund as co-investors. The company is led by founder and CEO Zhang Jinbao, with a chief scientific officer trained at Tsinghua and the University of Basel. It holds ISO 9001/14001/45001 certifications, has been recognized as a National High-Tech Enterprise and Shanghai 'Specialized, Refined, Differential and Innovative' SME, and has led the drafting of a group standard for cell therapy Leukopak raw materials while participating in a national PBMC preservation standard.

Milestone firmographics

Firmographics
Name
Milestone
Legal name
妙顺(上海)生物科技有限公司
Website
https://miles-bio.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Milestone (妙顺生物) is a Shanghai-based Chinese life-sciences tools company founded in 2014 that provides primary cells, cryopreservation reagents, magnetic separation platforms, and CRO services to biopharmaceutical companies, cell-and-gene-therapy developers, and academic research institutions, positioning itself as a domestic import substitute for upstream biopharma research materials.
Ownership category
akta.pro rank

Milestone industry classification

Industry
Product category
Biotechnology Research Services
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Medical and Diagnostic Laboratories (62151)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAK
Cell Therapy Quality, Analytics & Release Testing (potency, sterility, comparability)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Primary cell isolation
  • Cell therapy services
  • Cryopreservation solutions
  • Subcellular fractions
  • Drug discovery services

Where Milestone is headquartered

Location

Headquarters

HQ city
Zhangjiang
HQ country
China
HQ region
Asia

Offices6 records

Markets served

Milestone business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Primary Cell Products: One-time sale of isolated primary cells including PBMC, immune cell subsets (T cells, B cells, NK cells, monocytes), liver cells, and subcellular fractions (microsomes, S9 fraction). Revenue from direct product sales to biopharma companies and research institutions.
  2. Cell Isolation and Separation Services: Custom primary cell isolation services including hPB Leukopak collection, PBMC separation, immune cell subset isolation. Services include quality control, cryopreservation, and cold chain logistics.
  3. Biological Reagents and Consumables: Sale of cell culture media, cryopreservation solutions, magnetic separation beads, and related reagents. Consumable products with recurring purchase patterns.
  4. Drug Development Platform Services: CRO services including ADCC/ADCP assay, MLR testing, cytokine detection, and drug efficacy evaluation using primary cell models.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goCustom pricing based on cell type, species, donor characteristics, and service specifications

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Milestone product offering

Product offering

Core offering

Milestone (妙顺生物 / MileCell) provides primary cell isolation, separation, and cryopreservation products and services for biopharmaceutical companies, cell and gene therapy developers, and academic researchers. Its core offering is the proprietary TPCS platform delivering human primary cells (PBMC, immune cell subsets, liver cells, stem cells), animal primary cells across multiple species, subcellular fractions (microsomes, S9, lysosomes), biological matrices, SLC transporters, and cryopreservation reagents. It also offers tumor immunology CRO services including ADCC/ADCP assays, MLR testing, and drug efficacy evaluation using primary cell models.

Differentiator

Problem solved

Functional benefit

Brands

  • TPCS® (The Primary Cell Solution): Self-developed brand platform providing primary cell isolation services, cell culture reagents, and comprehensive cell technology services for drug discovery and development.
  • MileCell MagSep™
  • Kryogene™
  • 凌生科技 (Lingsheng Technology)

Products and services

  • Human Primary Cells — Healthy Donor & Disease Patient-Derived Catalog and custom-isolated human primary cells sourced from healthy donors and disease patients, for use by biopharmaceutical R&D, cell therapy developers, and academic researchers in immunology, oncology, and regenerative medicine studies.
  • Animal Primary Cells Multi-species animal primary cells for preclinical drug discovery, including immune cells, hepatocytes, intestinal epithelial cells, kidney proximal tubular epithelial cells, skeletal muscle cells, and brain microvascular endothelial cells for in vivo and in vitro pharmacology studies.
  • Subcellular Fractions (Microsomes, S9, Lysosomes) Subcellular fractions including liver microsomes, intestinal microsomes, liver S9, intestinal S9, induced liver S9, and liver lysosomes for ADME/DMPK and drug metabolism studies.
  • SLC Transporters (OAT1, OCT2, MOCK) Overexpression cell lines for SLC drug transporters OAT1 and OCT2 plus MOCK control cells, used in drug-drug interaction and renal/hepatic transport studies.
  • Biological Matrices (Bio-matrix) Healthy human donor biological matrices including blood-derived bio-matrix, other biological fluids, and tissue matrices used as assay matrices and reference standards.
  • Kryogene™ DMSO-Free Cryopreservation Solution Clinical-grade DMSO-free cryopreservation medium for immune cells, stem cells, and other primary cell types, eliminating the cytotoxic risks of DMSO while maintaining post-thaw viability and function.
  • Kryoplus™ Serum-Free Cryopreservation Solutions Serum-free and xeno-free cryopreservation media for immune cells and mesenchymal stem cells, designed for cost-efficient and regulatory-friendly cell storage.
  • MileCell MagSep™ Nanomagnetic Cell Separation Platform Proprietary nanomagnetic bead-based platform for multi-dimensional immune cell sorting, including positive selection kits (CD3, CD4, CD8, CD14) and negative selection panels, used for cell therapy and immunology research.
  • hPB Leukopak Collection Service Apheresis-based collection service for high-quality hPB Leukopak white blood cell samples, including healthy donor and mobilized donor collection plus irradiation and plateletpheresis/RBC/neutrophil collection options, for cell therapy raw material supply.
  • Tumor Immunology & Drug Efficacy Evaluation CRO Services CRO services for biopharmaceutical R&D including ADCC/ADCP assays, mixed lymphocyte reaction (MLR) testing, cytokine detection, and in vitro/in vivo drug efficacy evaluation using Milestone's primary cell models.
  • Custom Primary Cell Isolation & Separation Services Custom cell isolation and separation services for biopharma and cell therapy clients requiring tailored cell types, donor profiles, quality specifications, cryopreservation, and cold-chain logistics.

Quantifiable outcome

  • Cell viability ≥90% for frozen PBMC and immune cell products
  • +2 more outcomes

Companies that use Milestone

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Milestone technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Milestone partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered major.

  • MaoXing Bio (茂行生物)majorStrategic or Co-development Partner · 9 October 2023Strategic partnership for universal CAR-T development. Miaoshun provides PBMC raw materials for MaoXing's MT027 glioblastoma CAR-T product, supporting IND filing.
  • Xinxie Bio (欣协生物)majorStrategic or Co-development Partner · 14 September 2023Strategic cooperation to provide comprehensive CGT solutions. Xinxie provides cell therapy equipment while Miaoshun provides cell raw materials.
  • Baijun Bio (佰君生物)majorStrategic or Co-development Partner · 30 August 2023Strategic cooperation framework signed for preclinical drug discovery services integration. Combining Miaoshun's primary cells with Baijun's CRO platform to provide integrated drug discovery solutions.
  • Yinjia Bio (引加生物)majorStrategic or Co-development Partner · 30 August 2023Strategic partnership combining Miaoshun's cell products with Yinjia's protein technology platform to develop cell-related reagents for biopharma customers.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Milestone competitors and assessment

Company assessment

Direct peers

  • STEMCELL Technologies: Canadian-headquartered leader in primary cell isolation products (PBMC, immune cell subsets, leukopak), cell culture media, and cell separation reagents — the most direct global competitor to Milestone's TPCS primary cell platform across both research and CGT-manufacturing use cases.
  • Miltenyi Biotec: German provider of magnetic-bead cell separation (MACS), primary cells, leukopak, and cryopreservation media used across CGT manufacturing — directly comparable to Milestone's MileCell MagSep and TPCS offerings, and the global benchmark Milestone must displace in Chinese CGT labs.
  • ACROBiosystems: Beijing-headquartered provider of recombinant proteins, cell biology reagents, magnetic beads, and CGT process consumables — directly competes with Milestone in China for cell isolation reagents, magnetic separation tools, and bioprocess consumables.
  • Sino Biological: Chinese reagents and cell products supplier offering recombinant proteins, antibodies, and cell biology tools used in CGT and biopharma research — overlaps with Milestone's reagent and primary cell offerings for the same Chinese customer base.
  • CellGenix: German supplier of GMP-grade cell therapy raw materials including cryopreservation media, cytokines, and cell processing reagents — directly comparable to Milestone's Kryogene/Kryoplus and ancillary materials portfolio, particularly for clinical-grade cell therapy supply.
  • GenScript ProBio: GenScript's CDMO arm offering plasmid, viral vector, and cell therapy process services from China and the US — competes with Milestone in cell therapy enabling services and adjacent upstream bioprocess support.

Broad incumbents

  • Lonza: Swiss CDMO and primary cell/media supplier with a large Cell & Gene Technologies business serving global CGT developers — competes with Milestone in cell therapy raw materials and process development services but as part of a much broader biomanufacturing portfolio.
  • Bio-Techne: US life-science tools company with primary cells, leukopak, cytokines, and cell therapy reagents (R&D Systems, Tocris, PeproTech) — overlapping with Milestone's reagent, cell, and media product lines as part of a much wider proteomics and diagnostics franchise.
  • Charles River Laboratories: Large US CRO/CDMO with cell therapy services, primary cell products, and safety/analytics labs — overlaps Milestone's drug metabolism and cell-based CRO services, though Charles River operates across a far broader discovery-to-manufacturing portfolio.
  • WuXi AppTec: China's largest CRO/CDMO offering preclinical drug discovery, biologics, and cell therapy services — competes with Milestone in biopharma CRO services and liver-cell-based DMPK assays, though at significantly greater scale and breadth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Milestone financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Milestone leadership team

Management profile

Number of profiles

Profiles4 records

Milestone subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Milestone funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Milestone M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Milestone

What does Milestone do?

Milestone (妙顺生物 / MileCell) provides primary cell isolation, separation, and cryopreservation products and services for biopharmaceutical companies, cell and gene therapy developers, and academic researchers. Its core offering is the proprietary TPCS platform delivering human primary cells (PBMC, immune cell subsets, liver cells, stem cells), animal primary cells across multiple species, subcellular fractions (microsomes, S9, lysosomes), biological matrices, SLC transporters, and cryopreservation reagents. It also offers tumor immunology CRO services including ADCC/ADCP assays, MLR testing, and drug efficacy evaluation using primary cell models.

Is Milestone a public or private company?

Milestone is a private company. It is classified as venture growth investor backed and is currently operating.

When was Milestone founded?

Milestone was founded in 2014. It employs 51 to 100 people.

Where is Milestone based?

Milestone is headquartered in Zhangjiang, China, in the Asia region.

How does Milestone make money?

Four revenue lines are on record. Primary Cell Products are the primary driver. The others are cell Isolation and Separation Services, biological Reagents and Consumables and drug Development Platform Services.

Who are Milestone's main competitors?

Direct peers on record are STEMCELL Technologies, Miltenyi Biotec, ACROBiosystems, Sino Biological, CellGenix and GenScript ProBio. Broad incumbents are Lonza, Bio-Techne, Charles River Laboratories and WuXi AppTec.

Does Milestone have an API?

No public API is recorded for Milestone.

What industry is Milestone in?

Milestone's product category is Biotechnology Research Services. Its primary akta.pro industry code is HLAAABAH, Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals